IP Library › Granted Patent US 11,590,172
Granted Patent B2
US 11,590,172 · App. 16/296,463 · Granted Feb 28, 2023

Immunocompatible chorionic membrane products

Inventors: Samson Tom (Baltimore, MD); Alla Danilkovitch (Columbia, MD); Dana YOo (Falls Church, VA); Timothy Jansen (Baltimore, MD); Jin-Qiang Kuang (Woodstock, MD); Jennifer Michelle Marconi (Glen Burnie, MD)
Assignee: OSIRIS THERAPEUTICS, INC.
A61K35/28A01N1/0221A61K35/50A61K38/1825A61K38/1841A61K38/39A61K38/57C12N5/0605C12N2500/02C12N2501/115C12N2502/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,590,172
App. No.
16/296,463
Granted
Feb 28, 2023
Kind
B2
Abstract

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Claims (11)

1. A cryopreserved chorionic membrane comprising native therapeutic cells and matrix metalloproteinase-9 (MMP-9), wherein at least 70% of the native therapeutic cells in the chorionic membrane are viable, wherein the viable native therapeutic cells comprise one or more of mesenchymal stem cells (MSCs), stromal cells, and fibroblast cells, and wherein the cryopreserved chorionic membrane is substantially free of CD14+ macrophage cells.

2. The cryopreserved chorionic membrane of claim 1 , comprising: a cryopreserving amount of a cryopreservative; wherein the cryopreserved chorionic membrane comprises a reticular layer and a stromal layer that both comprise viable therapeutic cells, and wherein the cryopreserved chorionic membrane is substantially free of vascularized tissue or vascularized tissue derived immunogenic cells.

3. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane is substantially free of trophoblasts.

4. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane comprises insulin-like growth factor binding protein-1 and adiponectin.

5. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane has been disinfected.

6. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane has a square shape.

7. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane does not include an amniotic membrane.

8. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane has a thickness of 40 to 400 micrometers.

9. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane is substantially free of vascularized tissue or vascularized tissue-derived immunogenic cells.

10. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane comprises CD14+ macrophages in an amount of less than 5% of the amount of CD14+ macrophage cells in an unprocessed chorionic membrane.

11. The cryopreserved chorionic membrane of claim 1 , wherein the cryopreserved chorionic membrane has a width×length dimension of 5 centimeters by 5 centimeters.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2020
From: TOM, SAMSON; DANILKOVITCH, ALLA; YOO, DANA; JANSEN, TIMOTHY; KUANG, JIN-QIANG; MARCONI, JENNIFER MICHELLE
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 051713/0106 →
Continuity (6)
Continuation 14291256 · May 30, 2014
Continuation 13030507 · Feb 18, 2011
Provisional Application 61369562 · Jul 30, 2010
Provisional Application 61338464 · Feb 18, 2010
Provisional Application 61338489 · Feb 18, 2010
Related Publication 20200000853A1 · Jan 2, 2020